Operational cash flow remains structurally negative with quarterly outflows often exceeding $1.5M, further exacerbated by $1.4M in stock-based compensation during 2026Q1 that obscures underlying cash burn.
| Cash from Operations | -8M | -8.6M | -6.65M | -7.24M | -3.88M | -4.49M | -3.14M | -90.07K | -417.02K | 1.55M |
| Operating CF Margin % | - | -631.16% | - | - | - | -5985.92% | -10195.12% | - | - | - |
| Operating CF Growth % | -74.6% | -29.38% | 8.15% | -86.79% | 13.67% | -43.15% | -3382.03% | 78.4% | -126.84% | - |
| Net Income | -11.87M | -11.92M | -10.88M | -21.27M | -37.57M | -13.45M | -9.16M | -2.23K | -344.31K | 2.65M |
| Depreciation & Amortization | 1.23M | 1.22M | 1.04M | 1.04M | 1M | 447.41K | 323.43K | 0 | 0 | 0 |
| Stock-Based Compensation | 1.82M | 1.22M | 1.1M | 477.5K | 0 | 1.9M | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 5.34M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.91M | 2.34M | 2.21M | 10.79M | 33.25M | 4.26M | 3.03M | -88.28K | 0 | 0 |
| Working Capital Changes | -1.24M | -1.46M | -125.26K | 1.73M | -550.34K | -2.98M | 2.66M | 450 | -72.72K | -1.09M |
| Change in Receivables | -7.35K | -7.35K | -234.74K | -30.9K | -8.07K | 21.79K | -14.91K | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | -422.02K | 732.15K | 0 | 0 | 0 |
| Change in Payables | -109.49K | -381.01K | -149.94K | 1.32M | -35.07K | -1.58M | 1.47M | 0 | 0 | 0 |
| Cash from Investing | 591.52K | 0 | 0 | 0 | 0 | -1.75M | -75.75M | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | -1.75M | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | 0% | - | - | - | - | 2333.33% | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 85.41K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 8.35M | 13.74M | 5.71M | 4.92M | 5.49M | 8.22M | 2.9M | 90.57K | 570.2K | -1.55M |
| Debt Issued (Net) | 0 | 771.25K | 1.2M | -575K | -2.42M | -1.62M | 1.83M | 0 | 0 | 0 |
| Equity Issued (Net) | 7.64M | 12.97M | 4.01M | 5.29M | 3.27M | 9.89M | 1.07M | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -247.16K | 0 | 0 | 0 | 0 |
| Other Financing | 704.25K | 0 | 500K | 200K | 4.63M | -50.9K | 0 | 90.57K | 570.2K | -1.55M |
| Net Change in Cash | 942.82K | 5.14M | -936.25K | -2.32M | 1.61M | 1.98M | -237.12K | 505 | 153.18K | 383 |
| Free Cash Flow | -8M | -8.6M | -6.65M | -7.24M | -3.88M | -6.24M | -3.14M | -90.07K | -417.02K | 1.55M |
| FCF Margin % | -565.49% | -631.16% | - | - | - | -8319.25% | -10195.12% | - | - | - |
| FCF Growth % | -12.41% | -29.38% | 8.15% | -86.79% | 37.88% | -98.95% | -3382.03% | 78.4% | -126.84% | - |
| FCF per Share | -1.33 | -2.03 | -3.45 | -0.28 | -0.27 | -6.11 | -0.15 | -0.01 | -223.85 | 834.05 |
| FCF Conversion (FCF/Net Income) | 0.67x | 0.72x | 0.62x | 0.34x | 0.10x | 0.33x | 0.34x | 40.32x | 1.21x | 0.59x |
| Interest Paid | 2.19K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Insufficient cash runway
According to quarterly financial data, the persistent gap between net income and operating cash flow, evidenced by an OCF/NI ratio fluctuating between 0.42 and 1.09, suggests that non-cash adjustments and accruals significantly distort the company's reported profitability metrics relative to actual cash movement.
The volatility in the OCF/NI ratio indicates that net income is an unreliable proxy for the company's liquidity position. Investors should monitor how stock-based compensation and other non-cash charges continue to decouple the bottom line from the actual cash burn required to sustain clinical operations.
As reported in recent financial statements, the company consistently records negative free cash flow, with quarterly outflows frequently exceeding $1.5M, which highlights a structural inability to self-fund research and development activities through existing, sporadic licensing-based revenue streams without recurring external capital infusions.
The trajectory of free cash flow remains firmly in negative territory, reflecting the high-cost nature of pre-commercial biotechnology development. This trend suggests that the firm will remain dependent on equity markets until a major clinical milestone or commercial partnership significantly alters the revenue profile.
Based on historical cash flow data, working capital changes have shown erratic quarterly swings, including a notable $907.3K inflow in 2023Q4 followed by significant outflows, indicating that the company's cash position is highly sensitive to the timing of milestone payments and vendor settlement cycles.
The lack of a stable working capital cycle suggests that operational cash management is secondary to the timing of non-recurring revenue events. This inconsistency complicates cash forecasting and underscores the vulnerability of the firm's liquidity to delays in partnership-related cash inflows.
Analysis of the cash flow statement reveals that stock-based compensation, reaching as high as $1.4M in 2026Q1, serves as a primary non-cash add-back that obscures the true magnitude of the company's operational cash burn and the dilutive impact on existing shareholders over time.
By relying on stock-based compensation to manage cash expenses, the company effectively shifts the burden of funding R&D from the balance sheet to the equity base. This practice warrants further investigation into the long-term sustainability of talent retention and the potential for continued shareholder dilution.
Quick answers to the most common questions about buying COEPW stock.
Coeptis Therapeutics Holdings, Inc. (COEPW) generated $-8.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Coeptis Therapeutics Holdings, Inc. (COEPW) reported negative free cash flow of $8.6M in 2025, indicating capital requirements exceeded cash from operations.
Coeptis Therapeutics Holdings, Inc. (COEPW) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.